POSEIDA THERAPEUTICS INC
POSEIDA THERAPEUTICS INC logo
PSTX

POSEIDA THERAPEUTICS INC (PSTX)

$8.034.83%

Market is closed
– opens on 8 PM, 06 Feb 2023
  • $

1D

1W

1M

1Y

3Y

5Y

Key Stats

$7.59
Day's Range
$8.03
$1.82
52-Week Range
$8.03
1 month return21.67%
3 month return80.45%
1 year return85.02%
5 year return47.69%

Analyst Recommendation

based on 11 analysts ratings

Buy
90%
Buy
9%
Hold
0%
Sell

Based on 11 Wall street analysts offering stock ratings for POSEIDA THERAPEUTICS INC(by analysts ranked 0 to 5 stars)

Analyst Forecast

What analysts predicted

Upside of 84.31%

Current

$8.03

Target

$14.8

Recommendation Trend

Based on 11 analyst

Current1M Ago3M Ago
Buy
10
4
10
Hold
1
0
1
Sell
0
0
0
Consensus
BUY
BUY
BUY

Highlights

Market Capitalization658.4M
Book Value$2.52
Dividend Share0.0
Dividend Yield0.0%
Earnings Per Share (EPS)-2.32
Wall Street Target Price14.8

Valuation

Trailing PE0.0
Forward PE0.0
Price/Book (mrq)2.26
Enterprise Value301.6M
Enterprise Value/Revenue1.99
Enterprise Value/Ebitda-16.1

Technicals

Beta0.12
50 Day MA5.9
200 Day MA3.88

Institutional Holdings

FMR Inc

14.6%

Pentwater Capital Management LP

6.95%

EcoR1 Capital, LLC

3.08%

SILVERARC CAPITAL MANAGEMENT, LLC

2.97%

Vanguard Group Inc

2.77%

Paradigm Biocapital Advisors LP

2.41%

Company Information

Poseida Therapeutics is a clinical-stage biopharmaceutical company dedicated to utilizing our proprietary genetic engineering platform technologies to create next generation cell and gene therapeutics with the capacity to cure. Poseida has discovered and are developing a broad portfolio of product candidates in a variety of indications based on our core proprietary platforms, including its non-viral piggyBac® DNA Delivery System, Cas-CLOVER™ site-specific gene editing system and nanoparticle- and AAV-based gene delivery technologies. Its core platform technologies have utility, either alone or in combination, across many cell and gene therapeutic modalities and enable us to engineer its wholly-owned portfolio of product candidates that are designed to overcome the primary limitations of current generation cell and gene therapeutics.
OrganizationPOSEIDA THERAPEUTICS INC
Employees304
CEODr. Eric M. Ostertag M.D., Ph.D.
IndustryHealth Technology

Discover more

Frequently Asked Questions

What is POSEIDA THERAPEUTICS INC share price today?

Can Indians buy POSEIDA THERAPEUTICS INC shares?

How can I buy POSEIDA THERAPEUTICS INC shares from India?

Can Fractional shares of POSEIDA THERAPEUTICS INC be purchased?

What are the documents required to start investing in POSEIDA THERAPEUTICS INC stocks?

What are today’s High and Low prices of POSEIDA THERAPEUTICS INC?

What are today’s traded volumes of POSEIDA THERAPEUTICS INC?

What is today’s market capitalisation of POSEIDA THERAPEUTICS INC?

What is the 52 Week High and Low Range of POSEIDA THERAPEUTICS INC?

How much percentage POSEIDA THERAPEUTICS INC is down from its 52 Week High?

How much percentage POSEIDA THERAPEUTICS INC is up from its 52 Week low?

What are the historical returns of POSEIDA THERAPEUTICS INC?

Who is the Chief Executive Officer (CEO) of POSEIDA THERAPEUTICS INC?

Trading and brokerage services provided by

Banking and Remittance services provided by

Technology services provided by : Finzoomers Services Private Limited

Disclaimer: These services are not for exchange traded products.The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Finzoomers Services Private Limited acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*